Menu

Latest news & events

ERC Advanced Grant awarded to Prof. Andy Baker

ERC Advanced Grant awarded to Prof. Andy Baker

15 April 2024

Prof. Andy Baker (Dept of Pathology) has been awarded a European Research Council (ERC) Advanced Grant of €2,5M for his research project PolymiRize: Poly-miRNA targeting to prevent and reverse complex tissue remodelling after acute cardiovascular events'.

Read more
Longer and better lives for patients with atrial fibrillation

Longer and better lives for patients with atrial fibrillation

15 April 2024

An international panel of experts published recommendations to improve management of atrial fibrillation (AF).

Read more
More newsMore events
Carim Maastricht
Carim Maastricht

Judith Cosemans

Associate professor

Dr Judith Cosemans holds a master’s degree in Biological Health Sciences with specialisation in molecular biology from Maastricht University. She became fascinated to unravel the role of platelets in arterial thrombosis during her PhD research, which focussed on the dynamic regulation of thrombus stability. After finishing her PhD in 2009, she executed an award-winning postdoc project to develop flow chamber technology as a compatible alternative for experimental animal models of arterial thrombosis.

Dr Cosemans subsequently obtained two personal grants from the Dutch Heart Foundation (2011, 2015) and a Vidi grant from the Netherlands Organisation for Scientific Research (NWO, 2016). These grants facilitate her current research line, which lies on the interface of platelet signalling and vascular biology.

Her team aims to:
• provide novel mechanistic insight into the pathophysiology of thrombosis in the heart and in the brain
• develop better diagnostic tools and novel druggable targets to prevent recurrentthrombotic events

Judith-cosemans

Department of Biochemistry
Universiteitssingel 50, 6229 ER Maastricht
PO Box 616, 6200 MD Maastricht

  • 2024
    • Lemmens, T. P., Bröker, V., Rijpkema, M., Hughes, C. C. W., Schurgers, L. J., & Cosemans, J. M. E. M. (2024). Fundamental considerations for designing endothelialized in vitro models of thrombosis. Thrombosis Research, 236, 179-190. https://doi.org/10.1016/j.thromres.2024.03.004
  • 2023
    • Yakusheva, A., Slater, A., Payrastre, B., Garcia, C., D'Italia, G., Allan, H., Cosemans, J. M. E. M., Harper, M., Gawaz, M., Armstrong, P., Troitiño, S., Trivigno, S. M. G., Naik, U. P., & Senis, Y. A. (2023). Illustrated Abstracts of the 5th EUPLAN International Conference. Research and practice in thrombosis and haemostasis, 7(7), Article 102140. https://doi.org/10.1016/j.rpth.2023.102140
    • Schönichen, C., Montague, S. J., Brouns, S. L. N., Burston, J. J., Cosemans, J. M. E. M., Jurk, K., Kehrel, B. E., Koenen, R. R., Ní Áinle, F., O'Donnell, V. B., Soehnlein, O., Watson, S. P., Kuijpers, M. J. E., Heemskerk, J. W. M., & Nagy, M. (2023). Antagonistic Roles of Human Platelet Integrin aIIbβ3 and Chemokines in Regulating Neutrophil Activation and Fate on Arterial Thrombi Under Flow. Arteriosclerosis Thrombosis and Vascular Biology, 43(9), 1700-1712. https://doi.org/10.1161/ATVBAHA.122.318767
  • 2022
    • Karel, M. F. A., Roosen, M. G. C. H., Tullemans, B. M. E., Zhang, C. E., Staals, J., Cosemans, J. M. E. M., & Koenen, R. R. (2022). Characterization of cerebral small vessel disease by neutrophil and platelet activation markers using artificial intelligence. Journal of Neuroimmunology, 367, Article 577863. https://doi.org/10.1016/j.jneuroim.2022.577863
    • Lemmens, T. P., Coenen, D. M., Swieringa, F., Niessen, I. C. L., Coort, S. L. M., Koenen, R. R., Kutmon, M., & Cosemans, J. M. E. M. (2022). Finding the "switch" in platelet activation: prediction of key mediators involved in reversal of platelet activation using a novel network biology approach. Journal of Proteomics, 261, Article 104577. https://doi.org/10.1016/j.jprot.2022.104577
    • Karel, M. F. A., Tullemans, B. M. E., D'Italia, G., Lemmens, T. P., Claushuis, T. A. M., Kuijpers, M. J. E., & Cosemans, J. M. E. M. (2022). Corrigendum to "The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions" [Thromb. Res. 212 (2022) 72-80]. Thrombosis Research, 213, 113-113. https://doi.org/10.1016/j.thromres.2022.03.012
    • Karel, M. F. A., Tullemans, B. M. E., D'Italia, G., Lemmens, T. P., Claushuis, T. A. M., Kuijpers, M. J. E., & Cosemans, J. M. E. M. (2022). The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions. Thrombosis Research, 212, 72-80. https://doi.org/10.1016/j.thromres.2022.02.020
    • Cosemans, J. M. E. M. (2022). Platelet-derived MMP-2 in the prevention of plaque formation: how many strokes is par?European Heart Journal, 43(6), 515–517. https://doi.org/10.1093/eurheartj/ehab665
    • Karel, M. F. A., Lemmens, T. P., Tullemans, B. M. E., Wielders, S. J. H., Gubbins, E., van Beurden, D., van Rijt, S., & Cosemans, J. M. E. M. (2022). Characterization of Atherosclerotic Plaque Coating for Thrombosis Microfluidics Assays. Cellular and Molecular Bioengineering, 15(1), 55-65. https://doi.org/10.1007/s12195-021-00713-9
  • 2021
    • Heinzmann, A. C. A., Coenen, D. M., Vajen, T., Cosemans, J. M. E. M., & Koenen, R. R. (2021). Combined Antiplatelet Therapy Reduces the Proinflammatory Properties of Activated Platelets. TH open : companion journal to thrombosis and haemostasis, 5(4), e533-e542. https://doi.org/10.1055/a-1682-3415
Overview